Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Frost & Sullivan

May 12, 2021 – The biopharmaceutical industry is facing its biggest test in recent times. Biopharmaceutical companies must follow suit by adopting advanced manufacturing technologies, establishing public-private partnerships and placing sustainability at the core of the business strategy.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Frost & Sullivan

As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Healthcare News Press Releases artificial intelligence biopharmaceuticals biotechnology diagnostics Digital Health Pharmaceutical telehealth Virtual Care

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Healthcare News Press Releases Uncategorized artificial intelligence biopharmaceuticals biotechnology diagnostics Digital Health Pharmaceutical telehealth Virtual Care

First-time launchers in the pharmaceutical industry

McKinsey & Company

Increasingly, small biopharmaceutical companies are launching their new drugs themselves rather than relying on large pharma companies to do it for them.

Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome

Frost & Sullivan

Leveraging a leading suite of end-to-end biopharmaceutical development services covering patient-focused clinical trial design and decentralized clinical trial (DCT) strategies, the company has helped develop 198 of the 200 top-selling biopharmaceuticals in the market.

Global Water Scarcity and Hospitalization Rates Stimulate the Polymeric Membranes Market

Frost & Sullivan

Invest in Blood Transfusion and Apheresis Membranes to Accelerate Revenue Growth : The increasing demand for blood plasma to create plasma-derived biopharmaceutical products will drive the demand for apheresis and transfusion membranes.

LaVoieHealthScience Names James (Jim) Heins as Senior Vice President and Managing Director of its New York Practice

LaVoie Health Science Blog

In his new role, Heins will provide senior level communications counsel to LHS’s growing roster of biopharmaceutical, medical technology, health IT, and health care services clients. BOSTON & NEW YORK– NOVEMBER 12, 2020.

Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for Its Unmatched Breadth of Services to Support Clinical Trials

Frost & Sullivan

Furthermore, LabCorp Drug Development draws on its deep expertise in antiviral drugs and vaccines, as well as partners with biopharmaceutical companies to develop treatment and vaccines for COVID-19 through improved detection methods.”

Ecosystem Partnerships Extend and Evolve Alliances

Phoenix Consulting Group

Published by TIDWIT Inc. at June 2, 2020. An interview with Norma Watenpaugh, CEO & Founding Principal, Phoenix Consulting Group. Q: You have been involved with the channel and emerging ecosystems for some time. How has the concept of partnership evolved over the past several years?